Biotechnology News and Research

RSS

Novo A/S implement 10b5-1 trading plan for open market purchases of BioMimetic common stock

BioMimetic Therapeutics, Inc. and Novo A/S announced that on December 8, 2009, Novo A/S implemented a 10b5-1 trading plan, providing for open market purchases of BioMimetic common stock. Any transactions involving the Company's securities under the plan will be reported and disclosed as required by applicable securities laws.

9 Dec 2009

Phase 3 clinical trial results of RG1068 to be discussed

Repligen Corporation announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Wednesday, December 9th, 2009 at 8:30 a.m. EST, to discuss results of its Phase 3 clinical trial of RG1068 in MRI imaging of the pancreas.

9 Dec 2009

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.

9 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Epizyme closes Series B financing to a total of $40 million

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

9 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

Eli Lilly to pay Applied NeuroSolutions $250,000 for renewal of their collaboration

Applied NeuroSolutions, Inc., a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that Eli Lilly and Company has agreed to a one-year renewal of its drug discovery collaboration. Lilly will pay $250,000 to Applied NeuroSolutions for the one-year collaboration renewal.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

New room temperature-based liquid formulation for storage of tissues and cells

Biomatrica, the leader in room temperature biological sample stabilization, today announced the release of DNAgard(TM), the first room temperature-based liquid formulation for stabilization and storage of tissues and cells. The new DNAgard product adds to Biomatrica's portfolio of solutions for room-temperature storage, archiving, stabilization and transportation of biological samples.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Anesiva to merge with Arcion Therapeutics

Anesiva, Inc. announced today that the stockholders of Anesiva approved the merger with Arcion Therapeutics, Inc. ("Arcion") during its December 3, 2009 shareholder meeting. In connection with the merger, Anesiva stockholders also approved a one-for-forty reverse stock split, which will be effected upon the close of the merger.

8 Dec 2009

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

8 Dec 2009

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400.

8 Dec 2009

Anesiva receives notification letter from NASDAQ Stock Market

Anesiva, Inc. announced today that on December 2, 2009, Anesiva received a letter from The NASDAQ Stock Market ("Nasdaq") stating that Anesiva was required to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 during the last 30 consecutive business days and that therefore

8 Dec 2009

EPO grants patent for AbSorber's transplantation cross match-test

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Biotechnology News and Research

Novo A/S implement 10b5-1 trading plan for open market purchases of BioMimetic common stock

Phase 3 clinical trial results of RG1068 to be discussed

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

Memgen announces positive clinical data of ISF35 with chemotherapy

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Epizyme closes Series B financing to a total of $40 million

Scientists identify new potential drug for treating acute myeloid leukaemia

MCG receives $1.8M stimulus grant

Eli Lilly to pay Applied NeuroSolutions $250,000 for renewal of their collaboration

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

New room temperature-based liquid formulation for storage of tissues and cells

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Anesiva to merge with Arcion Therapeutics

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Anesiva receives notification letter from NASDAQ Stock Market

EPO grants patent for AbSorber's transplantation cross match-test

Specialty pharmaceutical market: Treatment patterns and product performance

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News